Takeda Yakuhin Kogyo Stock News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Takeda yakuhin kogyo stock. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Takeda Yakuhin Kogyo Stock Today - Breaking & Trending Today

Takeda Receives Positive CHMP Opinion for HYQVIA as Maintenance Therapy in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

15.12.2023 - Takeda (TSE:4502/NYSE:TAK) today announced the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of HYQVIA [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase] . ....

United States , Takeda Yakuhin Kogyo , Takeda Pharmaceutical Company Limited , Clinical Program , Peripheral Nerve Society , European Academy Of Neurology Peripheral Nerve Society , Exchange Commission , European Medicines Agency , European Academy Of Neurology , European Academy , Recombinant Human Hyaluronidase , Inflammatory Neuropathy Cause , Product Characteristics , Baxalta Innovations Gmbh , Pharmaceutical Company Limited , Annual Report , Peripher Nerv , Database Syst , Takeda Yakuhin Kogyo Stock , Takeda Yakuhin Kogyo Chart , Akeda Yakuhin Kogyo Kurs , Akeda Yakuhin Kogyo Aktie ,

Takeda Announces FY2023 H1 Results; Updates Full-Year Forecasts While Remaining on Track Towards Management Guidance

26.10.2023 - Takeda (TOKYO:4502/NYSE:TAK) today announced financial results for the first half of fiscal year 2023 (six months ended September 30, 2023), updating reported and Core forecasts and reconfirming Management Guidance for Core change at CER. Takeda . ....

United States , Takeda Yakuhin Kogyo , Takeda Pharmaceutical Company Limited , International Financial Reporting Standards , Exchange Commission , Constant Exchange Rate , Costa Saroukos , Management Guidance , Launch Products , Free Cash Flow , Core Forecasts , Reconfirming Management , Annual Report , Score Revenue , Core Operating , Core Net Profit , Net Debt , Free Cash , Takeda Yakuhin Kogyo Stock , Takeda Yakuhin Kogyo Chart , Akeda Yakuhin Kogyo Kurs , Akeda Yakuhin Kogyo Aktie ,

Takeda Reports Strong First Quarter FY2023 Results, Driven by Growth & Launch Products

27.07.2023 - Takeda (TOKYO:4502/NYSE:TAK) today announced strong financial results for the first quarter of fiscal year 2023 (period ended June 30, 2023). Takeda chief financial officer, Costa Saroukos, commented: “Our Growth & Launch Products continued to drive . ....

United States , Lang Schwarz , Takeda Yakuhin Kogyo , Constant Exchange Rate , Takeda Pharmaceutical Company Limited , Actual Exchange Rate , Exchange Commission , International Financial Reporting Standards , Free Cash Flow , Annual Report , Score Revenue , Core Operating , Core Net Profit , Net Debt , Free Cash , Takeda Yakuhin Kogyo Stock ,

Takeda to Acquire Late-Stage, Potential Best-in-Class, Oral Allosteric TYK2 Inhibitor NDI-034858 From Nimbus Therapeutics

13.12.2022 - Takeda (TSE:4502/NYSE:TAK) today announced that it will acquire NDI-034858 from Nimbus Therapeutics. NDI-034858 is an oral, selective allosteric tyrosine kinase 2 (TYK2) inhibitor being evaluated for the treatment of multiple autoimmune diseases . ....

United States , United Kingdom , Catherine Wilson , Nimbus Therapeutics , Takeda Yakuhin Kogyo , Jeb Keiper , Jun Saito , Christopher Oreilly , Research Development At Takeda , Nimbus Lakshmi Inc , Exchange Commission , Cleary Gottlieb Steen Hamilton , Takeda Pharmaceutical Company Limited , Program Subsidiary , Evercore Group , Andy Plump , Costa Saroukos , Antitrust Improvements Act , Cleary Gottlieb Steen , Rare Genetics , Plasma Derived Therapies , Pharmaceutical Company Limited , Annual Report , Nimbus Lakshmi , Acquire Late Stage , Potential Best In Class ,

Takeda's QDENGA▼ (Dengue Tetravalent Vaccine [Live, Attenuated]) Approved for Use in European Union

08.12.2022 - Takeda (TSE:4502/NYSE:TAK) today announced that the European Commission (EC) granted marketing authorization for the company’s dengue vaccine QDENGA (Dengue Tetravalent Vaccine [Live, Attenuated]) (TAK-003) for the prevention of dengue disease in . ....

Sri Lanka , United States , Dominican Republic , Takeda Yakuhin Kogyo , Tomas Jelinek , World Health Organization , Berlin Centre For , Data Monitoring Committee , Exchange Commission , European Union Eu Member States , Takeda Pharmaceutical Company Limited , European Centre For Disease Prevention , Medical Director , Berlin Centre , Tropical Medicine , Scientific Director , Dengue Efficacy Study , Fiscal Year , European Union , Member States , Product Characteristics , Latin America , Rare Genetics , Plasma Derived Therapies , Pharmaceutical Company Limited , Annual Report ,